RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .
ADMINISTRATION OF EXOGENOUS ERYTHROPOIETIN β AFFECTS LIPID PEROXIDATION AND SERUM PARAOXONASE‐1 ACTIVITY AND CONCENTRATION IN PREDIALYSIS PATIENTS WITH CHRONIC RENAL DISEASE AND ANAEMIA
1 Patients with advanced chronic renal disease and anaemia have decreased serum paraoxonase‐1 ( PON1 ) activity and an increased degree of oxidative stress compared with normal subjects . The present study investigated the effects of treatment of anaemia with exogenous recombinant erythropoietin ( EPO ) β and iron on levels of antibodies against oxidized low‐density lipoproteins ( ox‐LDL ) , as well as on serum PON1 activity and concentration , in predialysis patients with chronic renal disease . 2 Forty‐nine patients with chronic renal failure and haemoglobin ( Hb ) < 11 g/dL were treated over a period of 6 months with EPOβ ( 80–120 U/kg per week , s.c . ) and variable doses of iron . Selected biochemical variables were determined before and after treatment . 3 Treatment with EPOβ and iron was associated with a significant increase in mean ( ±SD ) blood Hb concentration compared with pretreatment values ( 12.8 ± 1.5 vs 9.9 ± 0.6 g/dL , respectively ; P < 0.001 ) . The average dose of EPOβ was 6160 ± 3000 U/week . After 6 months of treatment , compared with pretreatment values , the median levels ( 95 % confidence intervals ) of antibodies against ox‐LDL were decreased ( 17.5 ( 10.6–24.4 ) vs 24.8 ( 11.5–38.1 ) U/mL , respectively ; P < 0.001 ) , serum PON1 activity was slightly but significantly increased ( 123.6 ( 76.1–343.6 ) vs 101.0 ( 50.0–332.5 ) U/L , respectively ; P = 0.016 ) and the concentration of PON1 was significantly decreased ( 37.3 ( 11.8–76.2 ) vs 46.7 ( 24.6–98.0 ) mg/L , respectively ; P < 0.001 ) . There were no significant changes in total cholesterol , triglycerides or cholesterol fraction concentrations before and after treatment . 4 We suggest that EPOβ and iron treatment of anaemia promotes significant changes in serum PON1 activity and concentration and has a beneficial effect on oxidative stress in predialysis patients with chronic renal disease
RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .